Payers are continuing to implement copay accumulators and copay maximizers in an effort to counter copay assistance from pharmaceutical manufacturers. Research shows these programs target specialty drugs almost exclusively, so while they may provide short-term benefits to payers, in the long run they may result in higher downstream costs. As accumulators and maximizers come under fire from patient-advocacy groups and other stakeholders for their potential impact on patient outcomes, a new state law essentially banning these programs, as well as potential legal challenges, may pose difficulties for payers implementing them.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.